MedTrace Logo

Ametop - Friend and Foe A Prospective Study of the Incidence of Adverse Reactions With Ametop

NCT02750137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 192

Last updated 2016-04-25

No results posted yet for this study

Summary

Ametop was introduced into the formulary as it was deemed more efficacious for intravenous cannulation compared to EMLA. However, the incidences of adverse reactions seemed to be higher compared to other studies. This lead to a prospective observational study to look at the incidence and severity of skin reactions following routine clinical application of Ametop.

Conditions

  • Adverse Drug Event

Interventions

DRUG

Tetracaine

Application of Ametop prior to intravenous cannulation

Sponsors & Collaborators

  • KK Women's and Children's Hospital

    lead OTHER_GOV

Principal Investigators

  • Angela YJ Tan, MMed · KK Women's and Children's Hospital

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-05-31
Completion
2015-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02750137 on ClinicalTrials.gov